HopeStage
Back to all studies
Active Not RecruitingNCT04105231

Cannabidiol or risperidone for psychosis in people who have used cannabis

About this titleRead the official source — NCT04105231
Medication studyAges 18–45DenmarkSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
Glostrup MunicipalitySee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 1, 2021
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
64
Sponsor
Lone Baandrup
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Denmark
Age range
From 18 Years to 45 Years
Official registry ID
NCT04105231
Official title
Show the full official title

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Recruitment & locations

Not recruiting

Glostrup Municipality

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lone Baandrup.

Does this study involve medication?

Yes. The study involves medication, including Cannabidiol and Risperidone.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies